References
- 1Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol. 2021. DOI: 10.1038/s41569-021-00561-0
- 2Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016; 388(10046): 818–828. DOI: 10.1016/S0140-6736(16)31258-2
- 3Saglietto A, Scarsoglio S, Ridolfi L, Gaita F, Anselmino M. Higher ventricular rate during atrial fibrillation relates to increased cerebral hypoperfusions and hypertensive events. Sci Rep. 2019; 9(1):
3779 . DOI: 10.1038/s41598-019-40445-5 - 4Santos M, West E, Skali H, Forman DE, Nadruz WJ, Shah AM. Resting heart rate and chronotropic response to exercise: Prognostic implications in heart failure across the left ventricular ejection rraction spectrum. J Card Fail. 2018; 24(11): 753–762. DOI: 10.1016/j.cardfail.2018.09.015
- 5Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O’Neill G, Sharma A, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004; 43(7): 1201–1208. DOI: 10.1016/j.jacc.2003.11.032
- 6Houghton C, McCarthy M, Gillies K, Rousseau N, Wade J, Gamble C, et al. A study protocol of qualitative data sharing practices in clinical trials in the UK and Ireland: towards the production of good practice guidance. HRB Open Res. 2021; 4: 47. DOI: 10.12688/hrbopenres.13269.1
- 7Rodriguez F, Hong C, Chang Y, Oertel LB, Singer DE, Green AR, et al. Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic. J Am Heart Assoc. 2013; 2(4):
e000170 . DOI: 10.1161/JAHA.113.000170 - 8Cheung CC, Nattel S, Macle L, Andrade JG. Atrial fibrillation management in 2021: an updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines. Can J Cardiol. 2021. DOI: 10.1016/j.cjca.2021.06.011
- 9Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23): 1825–1833. DOI: 10.1056/NEJMoa021328
- 10Dilaveris PE, Gialafos EJ, Andrikopoulos GK, Richter DJ, Papanikolaou V, Poralis K, et al. Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clin Electrophysiol. 2000; 23(3): 352–358. DOI: 10.1111/j.1540-8159.2000.tb06761.x
- 11Management AIAFF-uIoR. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J. 2002; 143(6): 991–1001. DOI: 10.1067/mhj.2002.122875
- 12Investigators AFADS. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003; 42(1): 20–29. DOI: 10.1016/S0735-1097(03)00559-X
- 13Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612
- 14Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011; 58(17): 1795–1803. DOI: 10.1016/j.jacc.2011.06.055
- 15Groenveld HF, Tijssen, JG, Crijns HJ, Van den Berg MP, Hillege HL, Alings M, et al. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol. 2013; 61(7): 741–748. DOI: 10.1016/j.jacc.2012.11.038
- 16Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006; 8(11): 935–942. DOI: 10.1093/europace/eul106
- 17Pon G, Pelsue B, Gulbis B. Improving appropriate dosing of intravenous dilTIAZem in patients with atrial fibrillation or flutter with rapid ventricular response in the emergency department. J Emerg Nurs. 2020; 46(2): 246–253. DOI: 10.1016/j.jen.2019.10.011
- 18Steinberg BA, Kim S, Thomas L, Fonarow GC, Gersh BJ, Holmqvist F, et al. Increased heart rate is associated with higher mortality in patients with atrial fibrillation (AF): results from the outcomes registry for better informed treatment of AF (ORBIT-AF). J Am Heart Assoc. 2015; 4(9):
e002031 . DOI: 10.1161/JAHA.115.002031